Efficient treatment of colon cancer with codelivery of TRAIL and imatinib by liposomes

Author:

Fu Rongrong1,Chang Rui1,Peng Andong1,Feng Changshun1,Zhu Weifan1,Chen Yi1,Tian Xue1,Wang Rui1ORCID,Yan Hui1,Jia Dianlong1,Li Jun1

Affiliation:

1. Laboratory of Drug Discovery and Design, School of Pharmaceutical Sciences, Liaocheng University, Liaocheng, China

Funder

Shandong Provincial Natural Science Foundation

Youth Innovative Science and Technology Program of Shandong Colleges and University

Shandong Province Postgraduate Education Quality Improvement Plan

Publisher

Informa UK Limited

Reference36 articles.

1. Recent Progress in Bioconjugation Strategies for Liposome-Mediated Drug Delivery

2. Therapeutic applications of TRAIL receptor agonists in cancer and beyond

3. Imatinib and its combination with 2,5-dimethyl-celecoxibinduces apoptosis of human HT-29 colorectal cancer cells

4. The effect of celecoxib and its combination with imatinib on human HT-29 colorectal cancer cells: involvement of COX-2, Caspase-3, VEGF and NF-κB genes expression;Atari-Hajipirloo S;Cell Mol Biol (Noisy-le-Grand),2016

5. The c-kit tyrosine kinase inhibitor STI571 for colorectal cancer therapy;Attoub S;Cancer Res,2002

Cited by 1 articles. 订阅此论文施引文献 订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献

1. TRIAL-based combination therapies in cancers;International Immunopharmacology;2024-09

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3